Fenwal is supporting the start up of a U.S. Biovigilance Network, which will, for the first time, give the U.S. a national system to collect and analyze data on adverse reactions and incidents relating to the collection, transfusion and transplantation of human blood and use of related biological therapies. The ultimate goal is to enhance patient safety as well as reduce health care costs. Please see the press release on AABB's website for more information.